Should I buy or sell Aptose Biosciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks .

What is Aptose Biosciences' stock price target for 2024?

6 equities research analysts have issued 1 year price targets for Aptose Biosciences' stock. Their APTO share price targets range from $12.00 to $120.00. On average, they predict the company's stock price to reach $37.67 in the next year. This suggests a possible upside of 1,382.9% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts .

How have APTO shares performed in 2023?

Aptose Biosciences' stock was trading at $8.70 at the beginning of 2023. Since then, APTO shares have decreased by 70.8% and is now trading at $2.54. View the best growth stocks for 2023 here .

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our APTO earnings forecast .

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its earnings results on Thursday, November, 9th. The biotechnology company reported ($1.76) EPS for the quarter, beating the consensus estimate of ($2.16) by $0.40.

When did Aptose Biosciences' stock split?

Aptose Biosciences's stock reverse split on the morning of Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com . William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH) , Arch Therapeutics (ARTH) , Aurora Cannabis (ACB) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Anavex Life Sciences (AVXL) , CymaBay Therapeutics (CBAY) , Cisco Systems (CSCO) , Micron Technology (MU) and SCYNEXIS (SCYX) .

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:APTO

Aptose Biosciences (APTO) Stock Price, News & Analysis

$2.54

+0.08 (+3.25%)

(As of 12/29/2023 ET)

Compare

Today's Range: $2.43
▼
$2.57
50-Day Range: $2.22
▼
$3.20
52-Week Range: $2.14
▼
$11.55

Volume: 72,512 shs
Average Volume: 73,940 shs
Market Capitalization: $19.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.67

Aptose Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,382.9% Upside
$37.67 Price Target
Short Interest: Healthy
1.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($7.83) to ($5.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

583rd out of 950 stocks

Biological Products, Except Diagnostic Industry

102nd out of 158 stocks

3.5

Analyst's Opinion

Consensus Rating
Aptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.67, Aptose Biosciences has a forecasted upside of 1,382.9% from its current price of $2.54.
Amount of Analyst Coverage
Aptose Biosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.84% of the float of Aptose Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Aptose Biosciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptose Biosciences has recently increased by 193.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aptose Biosciences does not currently pay a dividend.
Dividend Growth
Aptose Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APTO.

2.5

News and Social Media Coverage

News Sentiment
Aptose Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Aptose Biosciences this week, compared to 1 article on an average week.
Search Interest
4 people have searched for APTO on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptose Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.53% of the stock of Aptose Biosciences is held by insiders.
Percentage Held by Institutions
Only 1.07% of the stock of Aptose Biosciences is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aptose Biosciences are expected to grow in the coming year, from ($7.83) to ($5.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aptose Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aptose Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aptose Biosciences has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptose Biosciences Stock (NASDAQ:APTO)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APTO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APTO Stock News Headlines

December 31, 2023 | americanbankingnews.com

Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

December 21, 2023 | benzinga.com

Aptose Biosciences Stock (NASDAQ:APTO), Guidance and Forecast

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription

December 5, 2023 | morningstar.com

Aptose Biosciences Inc APTO

December 4, 2023 | msn.com

Aptose Biosciences files to sell ordinary shares, warrants

December 1, 2023 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

November 12, 2023 | seekingalpha.com

Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript

November 11, 2023 | benzinga.com

Aptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning Calls

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

November 10, 2023 | benzinga.com

Aptose Biosciences: Q3 Earnings Insights

November 10, 2023 | markets.businessinsider.com

Promising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph Pantginis

November 9, 2023 | msn.com

Aptose Biosciences GAAP EPS of -$1.76 beats by $0.22

November 1, 2023 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)

November 1, 2023 | markets.businessinsider.com

Promising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy Rating

October 30, 2023 | finance.yahoo.com

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

October 16, 2023 | finance.yahoo.com

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

October 12, 2023 | theglobeandmail.com

Aptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)

September 8, 2023 | finance.yahoo.com

Companies Like Aptose Biosciences (TSE:APS) Could Be Quite Risky

September 7, 2023 | finance.yahoo.com

HANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC.

September 7, 2023 | markets.businessinsider.com

Expert Ratings for Aptose Biosciences

August 24, 2023 | finance.yahoo.com

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 23, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc down on Tuesday (APS)

August 18, 2023 | fool.com

Aptose Biosciences (NASDAQ: APTO)

August 11, 2023 | markets.businessinsider.com

RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know

August 11, 2023 | msn.com

Aptose Biosciences GAAP EPS of -$2.27 misses by $0.34

August 2, 2023 | msn.com

Aptose Biosciences (APTO) Price Target Increased by 1614.75% to 62.90

July 28, 2023 | finance.yahoo.com

Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

See More Headlines

Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APTO
CUSIP: N/A
CIK: 882361
Web: www.aptose.com
Phone: 858-926-2730
Fax: 905-234-2120
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $37.67
High Stock Price Target: $120.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +1,382.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.9281)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -230.97%
Return on Assets: -142.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.59
Quick Ratio: 1.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.13 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 7,820,000
Free Float: 7,072,000
Market Cap: $19.86 million
Optionable: Optionable
Beta: 1.32

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. William G. Rice Ph.D. (Age 59)
Chairman, Pres & CEO
Mr. Gregory K. Chow CPA (Age 45)
MBA, BA, Sr. VP, CFO & Principal Accounting Officer
Mr. Ernest Kitt B.S.
M.S, VP of Devel. & Technical Operations
Dr. Stephen B. Howell (Age 73)
Chief Medical Officer
Mr. Peter Murray
Director of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APTO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.
What is Aptose Biosciences' stock price target for 2024?: 6 equities research analysts have issued 1 year price targets for Aptose Biosciences' stock. Their APTO share price targets range from $12.00 to $120.00. On average, they predict the company's stock price to reach $37.67 in the next year. This suggests a possible upside of 1,382.9% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.
How have APTO shares performed in 2023?: Aptose Biosciences' stock was trading at $8.70 at the beginning of 2023. Since then, APTO shares have decreased by 70.8% and is now trading at $2.54.
View the best growth stocks for 2023 here.
When is Aptose Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our APTO earnings forecast.
How were Aptose Biosciences' earnings last quarter?: Aptose Biosciences Inc. (NASDAQ:APTO) posted its earnings results on Thursday, November, 9th. The biotechnology company reported ($1.76) EPS for the quarter, beating the consensus estimate of ($2.16) by $0.40.

When did Aptose Biosciences' stock split?: Aptose Biosciences's stock reverse split on the morning of Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?: 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.
What other stocks do shareholders of Aptose Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).
How do I buy shares of Aptose Biosciences?: Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APTO) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial